

Arild Nesbakken

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10812157/publications.pdf>

Version: 2024-02-01

69
papers

4,284
citations

126708

33
h-index

114278

63
g-index

71
all docs

71
docs citations

71
times ranked

7244
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive geriatric assessment can predict complications in elderly patients after elective surgery for colorectal cancer: A prospective observational cohort study. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 76, 208-217.	2.0	389
2	Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. <i>Lancet, The</i> , 2020, 395, 350-360.	6.3	364
3	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 207-216.	3.7	227
4	Portrait of the PI3K/AKT pathway in colorectal cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 104-121.	3.3	205
5	ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. <i>Gut</i> , 2012, 61, 1560-1567.	6.1	179
6	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. <i>Clinical Cancer Research</i> , 2018, 24, 794-806.	3.2	177
7	Frailty Is an Independent Predictor of Survival in Older Patients With Colorectal Cancer. <i>Oncologist</i> , 2014, 19, 1268-1275.	1.9	156
8	Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. <i>Molecular Cancer</i> , 2011, 10, 85.	7.9	126
9	MiR-9, -31, and -182 Deregulation Promote Proliferation and Tumor Cell Survival in Colon Cancer. <i>Neoplasia</i> , 2012, 14, 868-878.	2.3	124
10	ColoGuidePro: A Prognostic 7-Gene Expression Signature for Stage III Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2012, 18, 6001-6010.	3.2	109
11	DNA Sequence Profiles of the Colorectal Cancer Critical Gene Set KRAS-BRAF-PIK3CA-PTEN-TP53 Related to Age at Disease Onset. <i>PLoS ONE</i> , 2010, 5, e13978.	1.1	102
12	Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome. <i>International Journal of Cancer</i> , 2012, 131, 570-581.	2.3	100
13	Frailty indicators and functional status in older patients after colorectal cancer surgery. <i>Journal of Geriatric Oncology</i> , 2014, 5, 26-32.	0.5	84
14	Prognostic Impact of Lymph Node Harvest and Lymph Node Ratio in Patients With Colon Cancer. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 307-315.	0.7	83
15	A comparison of two pre-operative frailty measures in older surgical cancer patients. <i>Journal of Geriatric Oncology</i> , 2012, 3, 1-7.	0.5	80
16	Which elements of a comprehensive geriatric assessment (CGA) predict post-operative complications and early mortality after colorectal cancer surgery?. <i>Journal of Geriatric Oncology</i> , 2010, 1, 57-65.	0.5	79
17	The novel colorectal cancer biomarkers <i>CDO1</i> , <i>ZSCAN18</i> and <i>ZNF331</i> are frequently methylated across gastrointestinal cancers. <i>International Journal of Cancer</i> , 2015, 136, 844-853.	2.3	76
18	Distinct high resolution genome profiles of early onset and late onset colorectal cancer integrated with gene expression data identify candidate susceptibility loci. <i>Molecular Cancer</i> , 2010, 9, 100.	7.9	75

#	ARTICLE	IF	CITATIONS
19	Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival. <i>Genome Medicine</i> , 2011, 3, 32.	3.6	73
20	Lymph Node Micrometastases and Isolated Tumor Cells Influence Survival in Stage I and II Colon Cancer. <i>Diseases of the Colon and Rectum</i> , 2011, 54, 200-206.	0.7	73
21	Multilevel genomics of colorectal cancers with microsatellite instability—clinical impact of JAK1 mutations and consensus molecular subtype 1. <i>Genome Medicine</i> , 2017, 9, 46.	3.6	71
22	Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993–2010. <i>Acta Oncologica</i> , 2015, 54, 1714-1722.	0.8	70
23	B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome. <i>BMC Cancer</i> , 2014, 14, 602.	1.1	69
24	Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. <i>Clinical Cancer Research</i> , 2020, 26, 4107-4119.	3.2	68
25	Chromatin organisation and cancer prognosis: a pan-cancer study. <i>Lancet Oncology</i> , The, 2018, 19, 356-369.	5.1	67
26	Frailty measures, inflammatory biomarkers and post-operative complications in older surgical patients. <i>Age and Ageing</i> , 2010, 39, 758-761.	0.7	63
27	Prognostic Significance of β -Catenin, E-Cadherin, and SOX9 in Colorectal Cancer: Results from a Large Population-Representative Series. <i>Frontiers in Oncology</i> , 2014, 4, 118.	1.3	63
28	Phospholipase C Isozymes Are Deregulated in Colorectal Cancer – Insights Gained from Gene Set Enrichment Analysis of the Transcriptome. <i>PLoS ONE</i> , 2011, 6, e24419.	1.1	58
29	Quality of life in older and frail patients after surgery for colorectal cancer – A follow-up study. <i>Journal of Geriatric Oncology</i> , 2016, 7, 195-200.	0.5	55
30	Establishing Laparoscopic Roux-en-Y Gastric Bypass: Perioperative Outcome and Characteristics of the Learning Curve. <i>Obesity Surgery</i> , 2009, 19, 158-165.	1.1	48
31	Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. <i>British Journal of Cancer</i> , 2019, 121, 474-482.	2.9	41
32	CpG island methylator phenotype identifies high risk patients among microsatellite stable <i>BRAF</i> mutated colorectal cancers. <i>International Journal of Cancer</i> , 2017, 141, 967-976.	2.3	40
33	Prognostic, predictive, and pharmacogenomic assessments of <i>CDX2</i> refine stratification of colorectal cancer. <i>Molecular Oncology</i> , 2018, 12, 1639-1655.	2.1	40
34	Audit of Intraoperative and Early Postoperative Complications after Introduction of Mesorectal Excision for Rectal Cancer. <i>The European Journal of Surgery</i> , 2002, 168, 229-235.	1.0	35
35	Regulator of Chromosome Condensation 2 Identifies High-Risk Patients within Both Major Phenotypes of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3759-3770.	3.2	32
36	A Tissue-Based Comparative Effectiveness Analysis of Biomarkers for Early Detection of Colorectal Tumors. <i>Clinical and Translational Gastroenterology</i> , 2012, 3, e27.	1.3	30

#	ARTICLE	IF	CITATIONS
37	Post-discharge complications in frail older patients after surgery for colorectal cancer. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1542-1547.	0.5	30
38	Common Fusion Transcripts Identified in Colorectal Cancer Cell Lines by High-Throughput RNA Sequencing. <i>Translational Oncology</i> , 2013, 6, 546-555.	1.7	29
39	Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer. <i>Npj Genomic Medicine</i> , 2021, 6, 59.	1.7	29
40	Sentinel Node Mapping does not Improve Staging of Lymph Node Metastasis in Colonic Cancer. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 891-896.	0.7	27
41	Anticipating the Clinical Use of Prognostic Gene Expression-Based Tests for Colon Cancer Stage II and III: Is Godot Finally Arriving?. <i>Clinical Cancer Research</i> , 2013, 19, 6669-6677.	3.2	27
42	Long-term outcome of palliative treatment with self-expanding metal stents for malignant obstructions of the GI tract. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 1505-1514.	0.6	26
43	High Frequency of Fusion Transcripts Involving TCF7L2 in Colorectal Cancer: Novel Fusion Partner and Splice Variants. <i>PLoS ONE</i> , 2014, 9, e91264.	1.1	26
44	Alternative splicing expands the prognostic impact of <i>KRAS</i> in microsatellite stable primary colorectal cancer. <i>International Journal of Cancer</i> , 2019, 144, 841-847.	2.3	26
45	Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2. <i>Laboratory Investigation</i> , 2020, 100, 120-134.	1.7	26
46	Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. <i>EBioMedicine</i> , 2020, 59, 102923.	2.7	22
47	Patient-reported outcomes in palliative gastrointestinal stenting: a Norwegian multicenter study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2011, 25, 3162-3169.	1.3	21
48	The exon 4 level biomarker <i>SLC39A14</i> has organ-confined cancer specificity in colorectal cancer. <i>International Journal of Cancer</i> , 2012, 131, 1479-1485.	2.3	20
49	Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains. <i>Oncogene</i> , 2019, 38, 6109-6122.	2.6	20
50	High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2020, 19, e26-e47.	1.0	20
51	Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. <i>Oncogenesis</i> , 2019, 8, 35.	2.1	19
52	A novel transcript, <i>VNN1-AB</i> , as a biomarker for colorectal cancer. <i>International Journal of Cancer</i> , 2014, 135, 2077-2084.	2.3	18
53	Surgical options and trends in treating rectal prolapse: long-term results in a 19-year follow-up study. <i>Langenbeck's Archives of Surgery</i> , 2018, 403, 991-998.	0.8	17
54	Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer. <i>Clinical Epigenetics</i> , 2018, 10, 70.	1.8	14

#	ARTICLE	IF	CITATIONS
55	Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2340-2346.	0.5	14
56	Modeling and Validating the Cost and Clinical Pathway of Colorectal Cancer. <i>Medical Decision Making</i> , 2015, 35, 255-265.	1.2	12
57	Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. <i>Cancer Letters</i> , 2020, 469, 246-255.	3.2	12
58	Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy. <i>Cancer Medicine</i> , 2016, 5, 1840-1849.	1.3	11
59	Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000523.	2.0	11
60	Genomic and prognostic heterogeneity among <i>RAS/BRAF</i> ^{V600E} <i>TP53</i> mutated resectable colorectal liver metastases. <i>Molecular Oncology</i> , 2021, 15, 830-845.	2.1	11
61	Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. <i>European Journal of Health Economics</i> , 2020, 21, 321-334.	1.4	10
62	De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity. <i>Genome Medicine</i> , 2021, 13, 143.	3.6	10
63	Simultaneous Resection of Primary Colorectal Cancer and Synchronous Liver Metastases: Contemporary Practice, Evidence and Knowledge Gaps. <i>Oncology and Therapy</i> , 2021, 9, 111-120.	1.0	9
64	Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer. <i>Modern Pathology</i> , 2022, 35, 1236-1246.	2.9	8
65	Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer. <i>Acta Oncologica</i> , 2021, 60, 921-930.	0.8	7
66	Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. <i>ESMO Open</i> , 2020, 5, e001040.	2.0	6
67	Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases. <i>Journal of Translational Medicine</i> , 2021, 19, 384.	1.8	6
68	The expressed mutational landscape of microsatellite stable colorectal cancers. <i>Genome Medicine</i> , 2021, 13, 142.	3.6	4
69	E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models. <i>Molecular Oncology</i> , 2022, 16, 2312-2329.	2.1	4